Lucknow: Chandan Healthcare Limited (NSE – CHANDAN), – an integrated diagnostics company offering pathology and radiology services, reported strong business momentum during Q2 FY27, supported by healthy growth in its core diagnostics operations and continued expansion of its franchise network.

The Company’s Revenue from Diagnostics Operations grew by 46.66% YoY to ₹56.38 Cr in Q2 FY27, compared with ₹38.44 Cr in Q2 FY26. During the quarter, the Company also added 410 new franchises, taking its total franchise network to 685 as of 30th September 2026.

Q2 FY27 Financial Highlights

  • Revenue from Diagnostics Operations: ₹56.38 Cr, up 46.66% YoY from ₹38.44 Cr
  • Other Income: ₹14.65 Cr, compared with ₹2.56 Cr in Q2 FY26
  • Total Income: ₹71.03 Cr, up 73.22% YoY from ₹41.01 Cr
  • Total Income excluding One-Time Income: ₹59.00 Cr, up 43.89% YoY from ₹41.01 Cr

During Q2 FY27, the Company recognised one-time income of ₹12.03 Cr arising from the sale of its investment in the equity shares of Chandan Pharmacy Limited. This income is non-recurring and does not form part of the Company’s regular operations.

Q2 FY27 Financial Highlights

  • Added 410 franchises during Q2 FY27
  • Total franchise network expanded to 685
  • 25 Comprehensive Diagnostic Centres
  • 19 Diagnostic Centres
  • 25 Diagnostic Labs
  • 16 Radiology Labs

The Company continues to focus on scaling its diagnostics operations and expanding its network across pathology and radiology services. The strong Q2 FY27 growth and addition of 410 franchises reflect the continued expansion of its core diagnostics platform.